DDX3X and metabolic dysfunction-associated steatotic liver disease: Knockdown of DDX3X exacerbates HFD-induced hepatic steatosis, while further studies reveal that DDX3X ameliorates steatosis during NAFLD progression by inhibiting the mTORC1 signaling pathway (Liu P. et al., 2022).